Tufts University

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Duke University

The University of North Carolina at Chapel Hill

Musc Foundation for Research Development

Bryan P Toole

Shibnath Ghatak

Suniti Misra

Jian Liu

Stavros Garantziotis

John W Hollingsworth

Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer.

Uses of antagonists of hyaluronan signaling

Pharmaceutical compositions and methods for sensitizing multi-drug resistant cancer or radiation resistant cancer cells to chemotherapeutic agents are provided. Compositions include ligands of hyaluronan receptors, including glycosaminoglycans such as hyaluronan oligomers and derivatives of these oligomers, hyaluronan binding proteins, antibodies specific for hyaluronan receptors, hyaluronan mimetics, inhibitors of hyaluronan synthesis, and stimulators of hyaluronan degradation.

Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Growing community of inventors

Mt. Pleasant, SC, United States of America

Bryan P Toole